Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Caribou Biosciences, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented diagnosis of AML with either refractory or relapsed disease,
Non-proliferative disease
No more than 3 prior lines of therapy (induction, consolidation with or without allogeneic stem cell transplant, and maintenance are considered 1 line of therapy)
No available therapy with reasonable survival benefit
Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 and fit for allogeneic stem cell transplant
Adequate renal, hepatic, pulmonary, and cardiac function, with specific laboratory criteria
Women of child-bearing potential and men with a female partner who has child-bearing potential must agree to use acceptable, effective methods of birth control.
You may not be if
Acute promyelocytic leukemia
Extra-medullary disease (EMD) that is metabolically inactive by 18-FDG PET-CT
Prior treatment with CAR-T cell therapy
Allogeneic stem cell transplant within 100 days before lymphodepletion
Active graft-vs-host disease requiring therapy
Known active or prior history of central nervous system involvement
Seropositive for or history of human immunodeficiency virus (HIV)
Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion
Active hepatitis B or C infection
Primary immunodeficiency or autoimmune disease
Known life-threatening allergies, hypersensitivity, or intolerance to CB-012 or its excipients
